Tumor Necrosis Factor Receptor Superfamily, Member 14 (TNFRSF14) (N-Term) antibody

Details for Product No. ABIN265160
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

 
Antigen
Synonyms ATAR, CD270, HVEA, HVEM, LIGHTR, TR2, Atar, HveA, Hvem, Tnfrs14
Epitope
N-Term
(12), (12), (4), (2), (2), (1), (1), (1)
Reactivity
Human, Mouse (Murine)
(111), (21), (17)
Host
Rabbit
(74), (30), (6), (5), (4)
Clonality
Polyclonal
Conjugate
Un-conjugated
(8), (5), (3), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Application
Western Blotting (WB)
(67), (51), (42), (20), (13), (12), (11), (10), (6), (2), (2), (2), (1)
Pubmed 5 references available
Catalog no. ABIN265160
Quantity 0.1 mg
Price
368.50 $   Plus shipping costs $45.00
Shipping to United States (Change)
Availability Will be delivered in 6 to 8 Business Days

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen A 15 amino acid peptide from near the amino terminus of human TNFRSF14
Isotype IgG
Specificity This antibody detects TNFRSF14. Located in the membrane and widely expressed, with the highest expression in lung, spleen and thymus (6).
Purification Purified
Alternative Name TNFRSF14 / HVEM
Background Tumor necrosis factor receptor (TNFR) superfamily members are defined by cysteine-rich domains in their extracellular regions that bind TNF-related ligands that share a common structural homology in their extracellular domain. TNFRSF14 was initially identified as the Herpesvirus entry mediator and upon binding to the herpes simplex virus (HSV) envelope glycoprotein D or either of its natural ligands LIGHT and lymphotoxin alpha (LT), activates the transcription factors NF-kappaB and AP-1. Activation of this signal transduction pathway in T cells stimulates T cell proliferation and cytokine production, leading to inflammation and enhanced CTL-mediated tumor immunity, suggesting that these proteins may be useful as potential targets for controlling cellular immune responses.
Alternate names: HVEA, Herpesvirus entry mediator A, TR2, Tumor necrosis factor receptor superfamily member 14, Tumor necrosis factor receptor-like 2
Gene ID 8764
NCBI Accession NP_003811.2
UniProt Q92956
Application Notes Western Blot: 1 - 2 ug/ml. Positive Control: Raji Cell Lysate. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Format Liquid
Buffer Phosphate buffered saline with 0.02% sodium azide
Preservative Sodium azide
Handling Advice Avoid repeated freezing and thawing.
Storage -20 °C
Storage Comment Store the antibody (in aliquots) at -20 °C. Can be shipped at 2 - 8 °C.
Expiry Date 12 months
Supplier Images
anti-Tumor Necrosis Factor Receptor Superfamily, Member 14 (TNFRSF14) (N-Term) antibody anti-Tumor Necrosis Factor Receptor Superfamily, Member 14 (TNFRSF14) (N-Term) antibody
Background publications Montgomery, Warner, Lum et al.: "Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family." in: Cell, Vol. 87, Issue 3, pp. 427-36, 1996 (PubMed).

Marsters, Ayres, Skubatch et al.: "Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1." in: The Journal of biological chemistry, Vol. 272, Issue 22, pp. 14029-32, 1997 (PubMed).

Mauri, Ebner, Montgomery et al.: "LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator." in: Immunity, Vol. 8, Issue 1, pp. 21-30, 1998 (PubMed).

Granger, Rickert: "LIGHT-HVEM signaling and the regulation of T cell-mediated immunity." in: Cytokine & growth factor reviews, Vol. 14, Issue 3-4, pp. 289-96, 2003 (PubMed).

Watts: "TNF/TNFR family members in costimulation of T cell responses." in: Annual review of immunology, Vol. 23, pp. 23-68, 2005 (PubMed).

Hosts (74), (30), (6), (5), (4)
Reactivities (111), (21), (17)
Applications (67), (51), (42), (20), (13), (12), (11), (10), (6), (2), (2), (2), (1)
Conjugates (8), (5), (3), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Epitopes (12), (12), (4), (2), (2), (1), (1), (1)
back to top